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6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoform 3 (PFKFB3) is
a key enzyme of the glycolytic pathway, and it plays an essential role in
angiogenesis. 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) is fre-
quently used as a glycolysis inhibitor and is thought to inhibit PFKFB3.
However, this latter effect of 3PO has never been investigated in detail and
was the aim of the present study. To demonstrate binding of 3PO to
PFKFB3, we used isothermal titration calorimetry. However, 3PO did not
bind to PFKFB3, even up to 750 µM, in contrast to 3 µM of AZ67, which is
a potent and specific PFKFB3 inhibitor. Instead, 3PO accumulated lactic
acid inside the cells, leading to a decrease in the intracellular pH and an inhi-
bition of enzymatic reactions of the glycolytic pathway.
Keywords: 3PO; glycolysis; intracellular pH; isothermal titration
calorimetry; PFKFB3
Glycolysis is an essential bioenergetic pathway in
endothelial cells (ECs) generating up to 85% of total
cellular ATP. A key regulating enzyme in the gly-
colytic pathway is 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase (PFKFB), which is involved in
both synthesis and degradation of fructose-2,6-bispho-
sphate. Among the four known PFKFB isoforms, only
PFKFB isoform 3 (PFKFB3) reveals a kinase-to-phos-
phatase ratio of about 740 : 1, which favors the for-
mation of intracellular fructose-2,6-bisphosphate (Fru-
2,6-P2) and enhanced glycolysis [1,2]. Interestingly, the
expression of PFKFB3 is upregulated in response to
hypoxia and inflammatory stimuli [3,4]. Because silenc-
ing or inactivation of PFKFB3 reduces glycolysis and
impairs vessel sprouting [5], PFKFB3 has become an
attractive therapeutic target in preventing pathological
angiogenesis. 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-
1-one (3PO) has been reported as a novel compound
that reduces glycolytic flux through competitive inhibi-
tion of PFKFB3 [6]. It causes a rapid reduction in
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Fru-2,6-P2 levels and inhibits tumorigenic growth
in vivo. It also diminishes 18F-2-DG uptake within
xenografts [6] and inhibits EC proliferation and migra-
tion, resulting in reduced vessel sprouting in EC
spheroids, zebrafish embryos, and the postnatal
mouse retina. Notably, all these effects of 3PO are
attributable to only partial and transient inhibition of
glycolysis [7].
Although 3PO and the more potent analogue
PFK15 are considered to act as PFKFB3 inhibitors
[8–12], thorough experimental evidence is currently
lacking. Moreover, recent data indicate that 3PO is
inactive in a PFKFB3 kinase assay (IC50 > 100 µM)
and no crystal structure is available confirming binding
of 3PO to PFKFB3 kinase [13]. It should be noted
that 3PO does not inhibit the enzymatic activity of
other enzymes involved in the glycolytic pathway such
as hexokinase, glucose-6-phosphate dehydrogenase,
transketolase, phosphofructokinase, pyruvate kinase,
and lactate dehydrogenase [7]. In the present study, we
demonstrate that the antiglycolytic activity of 3PO
relies on its ability to interfere with intracellular milieu
acidification, rather than on a direct binding to
PFKFB3.
Materials and methods
Glycolysis measurements
Glycolysis was measured in vitro using a Glycolysis Cell-
Based Assay Kit (Cayman Chemical, Ann Arbor, MI,
USA) following the manufacturer’s instructions. Briefly,
human umbilical vein ECs (HUVECs) were seeded in a 96-
well culture plate at a density of 15 000 cells per well and
incubated overnight at 37 °C in M199 culture medium,
supplemented with 0.25% heat-inactivated FBS, 1%
nonessential amino acids (NEAA), and antibiotics. There-
after, cells were treated with 3PO (Sigma-Aldrich, Saint
Louis, MO, USA; 2–100 µM) for 24 h and assayed to deter-
mine the L-lactate concentration in the culture medium. A
neutral red viability assay was performed as described [14]
to test cell viability.
Glycolytic flux was also assessed in HUVECs by measur-
ing the extracellular acidification rate (ECAR) using a Sea-
horse XFp Analyzer (Agilent Technologies, Santa Clara,
CA, USA) and following manufacturer recommended pro-
tocol. ECAR values were expressed in units of mpHmin1,
which follow the changes in pH in the media surrounding
the cells, an acidification mostly due to glycolytic proton
efflux [15]. Assays were performed prior to experiments to
determine optimal cell seeding density, viability, and opti-
mal concentrations of each compound. Briefly, 10 000
HUVECs per well were plated into XF8 polystyrene cell
culture plates. After 16 h of incubation at 37 °C, cells were
treated with 3PO (0, 20 or 40 lM) for 5 h. Prior to per-
forming a glycolysis stress test, growth medium in the wells
of XF cell plates was exchanged with the appropriate Sea-
horse assay medium (Agilent Technologies, 103335-100).
Baseline rates were measured three times prior to any injec-
tion. Firstly, glucose (Sigma-Aldrich, G8270; 10 mM final
concentration) was injected into the medium to provide a
measure of glycolytic rate. Subsequently, oligomycin, a
mitochondrial ATP synthase inhibitor (Sigma-Aldrich,
75351; 2 µM final concentration) was injected, blocking
oxidative phosphorylation and giving an estimate of gly-
colytic capacity. Finally, 2-DG (Sigma-Aldrich, D8375;
50 mM final concentration) was injected, which is a glucose
analog that inhibits glycolysis, providing an estimate of
nonglycolytic acidification. All compounds were prepared
in assay medium and adjusted to pH 7.4. Glycolytic capac-
ity was calculated as the difference between ECAR follow-
ing the injection of 2 lM oligomycin and the basal ECAR
reading [16].
Intracellular lactate measurements
Intracellular lactate levels were measured in vitro using an
L-Lactate Assay Kit (Cayman Chemical) according to the
manufacturer’s protocol. HUVECs were plated into a cell
culture plate until 80% confluency in M199 growth med-
ium supplemented with 20% FBS, 1% NEAA, and antibi-
otics. Next, HUVECs were treated with 3PO (20 µM) or
vehicle (DMSO) for 24 h. A cell count was performed with
an automated cell counter (Countess II FL; Life Tech-
nologies, Carlsbad, CA, USA). After deproteinization with
0.25 M metaphosphoric acid, potassium carbonate (5 M)
was added to the cell pellet to neutralize the acid. Follow-
ing centrifugation (10 000 g for 5 min) at 4 °C, the super-
natant was used for assaying. Lactate fluorescent substrate
was used as a fluorophore while fluorescence
(kex = 540 nm; kem = 595 nm) was measured and normal-
ized to the cell number. 2-Cyano-3-(4-hydroxyphenyl)-2-
propenoic acid (CHC), a classical inhibitor of monocar-
boxylate transporters (MCTs), was used as a reference
compound.
Intracellular pH assay
Intracellular pH (pHi) changes were measured with a Fluo-
rometric pHi Assay Kit (Sigma-Aldrich, MAK150) follow-
ing the manufacturer’s protocol. In brief, HUVECs were
plated overnight in M199 growth medium supplemented
with 20% FBS, 1% NEAA, and antibiotics in a 96-well
culture plate. Subsequently, the fluorescent pH indicator
BCFL-AM was added for 30 min. 3PO (20 µM) was diluted
in Hank’s Buffer (HBSS) containing 20 mM HEPES and
added to the cells. Fluorescence (kex = 490 nm;
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kem = 535 nm) was measured 5 h after addition of 3PO.
CHC, a well-known inhibitor of MCTs, was used as a ref-
erence compound.
In vitro angiogenesis assay
Inhibition of endothelial tube formation by 3PO was moni-
tored using an in vitro angiogenesis assay kit (Millipore,
Burlington, MA, USA) following the manufacturer’s
instructions. Briefly, HUVECs were cultured in M199 med-
ium supplemented with 20% FBS, 1% NEAA, and antibi-
otics. After addition of 3PO (0–20 µM) for 16 h, changes in
tube formation and formation of cellular networks were
evaluated. Capillary tube branching points were counted in
five random fields per concentration.
Endothelial cell migration assay
Murine immortalized heart ECs (H5V) were cultured on
12-well plates in Dulbecco’s Modified Eagle’s medium
(DMEM) medium supplemented with 10% FBS and antibi-
otics. After reaching confluence, H5V were starved over-
night in DMEM containing 0.5% FBS. Each well was
marked below the plate surface by drawing a vertical line.
Five different scratches intercepting the marked line were
done in each well using a 200-lL sterile tip. Pictures of
scratches were taken before and after 18 h of incubation
with DMEM (with 2.5% FBS) with or without 3PO
(20 lM) and with or without vascular endothelial growth
factor (VEGF, 10 ngmL1). Next, the mean closure of five
different scratches was analyzed using IMAGEJ software
(National Institutes of Health, Bethesda, MD, USA). EC
migration was expressed as the percentage of scratch clo-
sure after 18 h vs the initial area by using the following
formula: % closure = [(scratched area at 0 h  scratched
area at 18 h)/scratched area at 0 h] 9 100.
Aortic sprouting
An aortic ring assay was performed as previously described
[17]. In brief, murine thoracic aortas were dissected, cleaned
under sterile conditions, transferred to 10-cm culture dishes,
and cut into 0.5-mm thick rings with a sterile scalpel. After
overnight starvation in serum-free Opti-MEM at 37 °C,
ring segments were transferred into wells of a 96-well plate
coated with 50 µL of a freshly prepared collagen type I
solution (1 mgmL1). The aortic rings remained in Opti-
MEM (supplemented with 2.5% FBS and antibiotics) in
the presence or absence of 3PO and/or VEGF
(50 ngmL1; R&D Systems, Minneapolis, MN, USA).
Medium was replaced every 2 days. On day 6, rings were
fixed with 4% paraformaldehyde, stained with von Wille-
brand factor antibody (anti-vWF, PC054, Binding Site) and
DAPI prior to fluorescence microscopy imaging. The
number of sprouts was counted for each ring, and sprout
numbers per ring were averaged for each group and
graphed.
Isothermal titration calorimetry
Binding of 3PO and AZ PFKFB3 67 (further abbreviated
as AZ67, Tocris, used as control) to PFKFB3 was analyzed
by calorimetry using a MicroCal Peaq-ITC isothermal titra-
tion calorimeter (nonautomated version; Malvern Panalyti-
cal, Malvern, UK). Prior to ITC analysis, recombinant
human PFKFB3 from Escherichia coli [Flemish Institute
for Biotechnology (VIB), Protein Service Facility, Univer-
sity of Ghent, Belgium] was dialyzed against 2 L buffer
(40 mM Tris, 500 mM NaCl, 5 mM MgCl2, 2 mM DTT at
pH 7.4) for 2 h at 4 °C under constant stirring, followed
by switching to a novel 2 L buffer vial and overnight dialy-
sis. For this purpose, Slide-A-Lyzer Dialysis G2 cassettes
(Thermo Fisher Scientific, Waltham, MA, USA) were used.
The concentration of the sample after dialysis was deter-
mined through UV-absorbance at 280 nm using a Spec-
traMax Plus 384 (Molecular Devices, San Jose, CA, USA).
A small portion of the second dialysis buffer volume was
kept for matching the ligand solutions (AZ67 or 3PO). All
buffers were prepared in ultrapure water (18.2 MO.cm),
equilibrated to room temperature, and degassed for 15 min
in an ultrasonication bath before use. All titrations were
performed with the same PFKFB3 sample, diluted to a
working concentration of 3 µM, and with the same titration
conditions (except for the ligand concentration) in order to
allow mutual comparison between the different runs.
The reference cell of the Peaq-ITC was filled with
degassed ultrapure water. The PFKFB3 solution was put in
the sample cell after a 2 min pre-equilibration with assay
buffer (same recipe as dialysis buffer). The ligand solution
was administered in the injection syringe. Titration condi-
tions were as follows: One initial injection of 0.4 µL was
followed by 14 injections of 2.5 µL. The initial spacing was
set to 180 s, while the remaining spacing was set to 150 s.
The sample cell was continuously stirred at 750 r.p.m.
Temperature was set to 37 °C before loading and kept con-
stant during the complete run. The DP (differential power
between the reference and sample cells to maintain a zero
temperature difference between the cells) was set to 5.
To determine the dilution heats for each PFKFB3-ligand
concentration combination, control titrations were per-
formed consisting of injection of ligand into the buffer-filled
cell (thus in the absence of PFKFB3, without binding).
Thermograms were analyzed using the MICROCAL PEAQ-ITC
ANALYSIS software (Malvern Pananalytical), using the ‘one
set of sites’ binding model, by including the corresponding
control titration. In order to visually compare the different
titrations with completely different molar ratios, the data
were transformed to generated heat (ΔH) per injection.
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Statistics
All data are expressed as mean  SEM. Statistical analyses
were performed using SPSS software (version 25; IBM,
Armonk, NY, USA). Statistical tests are specified in the fig-
ure legends. N indicates the number of times an experiment
has been repeated. Differences were considered significant
at P < 0.05.
Results
3PO inhibits glycolysis in endothelial cells
Lactate measurements in the culture medium of
HUVECs as well as Seahorse ECAR measurements
showed that 3PO inhibits glycolysis in a concentra-
tion-dependent manner (Fig. 1A,B). The ECAR
diminished by more than 50% after treatment with
20 lM 3PO (Fig. 1B). Viability of HUVECs was not
affected when cells were treated with 3PO up to
20 lM (Fig. 1C). However, cytotoxic effects were
noticed after exposure to higher 3PO concentrations
(40 and 100 µM).
3PO inhibits capillary tube formation, EC
migration, and formation of aortic sprouts
To confirm whether glycolysis inhibition by 3PO in
ECs affects neoangiogenesis, an in vitro Matrigel
assay with HUVECs was performed. This assay is
based on the ability of ECs to form cord and mesh
structures when seeded on a growth factor-enriched
matrix. 3PO fully inhibited cord formation at
20 µM. At lower concentrations (5–10 µM), mesh
structures consisting of EC chords were visible but
their numbers were reduced in a concentration-de-
pendent manner. A healthy network of chord struc-
tures was formed in the absence of 3PO (Fig. 2A).
Branch point counting demonstrated an inverse cor-
relation between the amount of branch points and
the concentration of 3PO (Fig. 2B). Apart from
inhibition of capillary tube formation, 3PO inhib-
ited EC migration after scratching EC monolayers
(Fig. 3) and prevented aortic sprouting (Fig. 4)
both under basal conditions and after stimulation
with VEGF.
3PO does not bind PFKFB3
Isothermal titration calorimeter measurements did not
show any binding of 3PO toward recombinant
PFKFB3. Even usage of 750 µM 3PO as final concen-
tration did not yield any binding indication. In con-
trast, AZ67, which is a potent and specific PFKFB3
inhibitor [13] that was used as a positive control
clearly showed binding toward recombinant PFKFB3
(Fig. 5A).
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Fig. 1. 3PO inhibits glycolysis in vitro. (A)
HUVECs were cultured and treated with
3PO (2–100 µM) for 24 h. Extracellular
lactate was measured to evaluate
glycolysis. (B) Glycolytic flux was
assessed by measuring the ECAR using a
Seahorse XFp Analyzer. Cultured HUVECs
were treated without or with 3PO (20 or
40 µM) for 5 h. (C) 3PO (2, 10, 20 lM) did
not show cytotoxic effects up to 24 h of
treatment compared to vehicle (DMSO),
whereas concentrations starting from
40 µM 3PO onward decreased cell viability.
**P < 0.01, ***P < 0.001 (one-way
ANOVA followed by Dunnett test, N = 3).
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3PO induces intracellular lactate accumulation
and decreases the intracellular pH
Disruption of the pHi has been shown to play an impor-
tant role in regulating angiogenesis [18] and glycolysis
[18,19]. Therefore, we studied the effect of 3PO treatment
on the pHi in ECs. 3PO (20 lM) induced intracellular
acidification, as shown by a significant decrease in pHi in
HUVECs (Fig. 5B). Given that lactate is an important
regulator of pH [20], we measured intracellular lactate
levels in HUVECs after treatment with 3PO and showed
that it increased the lactate concentration intracellularly
(Fig. 5C). CHC, a well-known inhibitor of MCTs [21],
was used as a reference compound.
Discussion
The rate of glycolysis in ECs is much higher than in
any other healthy cell type. Accordingly, the majority
of ATP produced in these cells is through the anaero-
bic glycolytic pathway. These findings highlight glycol-
ysis inhibition as a promising antiangiogenic strategy.
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Fig. 2. 3PO inhibits EC tube formation. (A) Representative images
of an in vitro angiogenesis assay. HUVECs were seeded on
ECMatrix in the presence or absence of 3PO (5, 10, 20 µM) for
16 h. Images of tube formation and branching were taken and
quantified. Scale bar = 100 µm. (B) The progression of
angiogenesis was quantified by counting the amount of capillary
tube branch points at different concentrations. *P < 0.05 vs control
(Mann–Whitney U-test, N = 4).
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Fig. 3. 3PO inhibits EC migration. (A) Representative images of a
scratch assay. Murine immortalized heart ECs (H5V) were starved,
subsequently wounded, and treated with DMEM (2.5% FBS) with
or without 20 µM 3PO, and with or without 10 ngmL1 VEGF for
18 h. (B) The wound area was measured at 0 and 18 h, and
migration was quantified. Factorial ANOVA, N = 5–7; effect of
3PO: P = 0.020; effect of VEGF: P = 0.046; interaction: P = 0.255;
*P < 0.05.
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Using computational techniques, 3PO was identified as
a small-molecule inhibitor of PFKFB3 [6]. Follow-up
experiments indicate that 3PO reduces Fru-2,6-P2
levels and glycolytic flux [6]. Since then, administration
of 3PO has been considered as an attractive therapeu-
tic strategy in cancer research, acute lung injury, lung
fibrosis, and atherosclerosis [22–25]. The ability of
3PO to inhibit glycolysis was confirmed in the present
study. Indeed, by using Seahorse technology, we could
demonstrate that 3PO inhibits glycolysis in a concen-
tration-dependent manner in HUVECs, resulting in an
up to 50% reduction in glycolytic rate. Moreover, 3PO
inhibits capillary tube formation, migration of ECs,
and formation of aortic sprouts, which are all pro-
cesses that heavily depend on glycolysis. However, an
enzyme binding assay via ITC did not reveal binding
of 3PO to PFKFB3, not even when titrating with up
to 750 µM final concentration, which is more than 35
times higher than the 20 µM 3PO used in the in cellulo
experiments. This raises considerable doubts as to
whether 3PO does work via PFKFB3 inhibition.
Importantly, 3PO does not inhibit the enzymatic activ-
ity of other enzymes involved in the glycolytic path-
way, such as hexokinase, glucose 6-phosphate
dehydrogenase, transketolase, glyceraldehyde 3-
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Fig. 4. 3PO inhibits aortic sprouting. (A) Aortic rings from ApoE/
mice were embedded in collagen type I and treated with Opti-
MEM (supplemented with 2.5% FBS) in the presence or absence
of 20 µM 3PO and/or VEGF (50 ngmL1) 2.5% (vol/vol) FBS or
VEGF 50 ngmL1. At day 6, rings were fixed and stained to
delineate ECs. Images of ring sprouting were obtained and
quantified. Scale bar = 1 mm. (B) Sprouts were quantified, N = 4
mice. ***P < 0.001 Factorial ANOVA, effect of 3PO: P < 0.001,
effect of VEGF: P < 0.001, interaction: P < 0.001.
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Fig. 5. Mechanism of glycolysis inhibition by 3PO. (A) 3PO does
not bind to PFKFB3. Binding of 3PO to PFKFB3 was analyzed via
calorimetry using a MicroCal ITC ITC. Discharged or absorbed heat
during the eventual interaction between the PFKFB3 protein and
3PO (3–750 µM) was measured ((ΔH). PFKFB3 inhibitor AZ67
(3 µM) was used as a positive control. Indicated concentrations are
the concentrations in the injection syringe of the Peaq-ITC, N = 3.
(B) 3PO decreases the pHi. HUVECs were treated with 3PO
(20 µM) for 5 h. Fluorescent pH indicator BCFL-AM was added, and
fluorescence was measured. CHC (2 mM) was used as a positive
control, N = 6–20. ***P < 0.001 vs control (one-way ANOVA
followed by Dunnett test). (C) 3PO induces intracellular lactate
accumulation. HUVECs were treated with 3PO (20 µM) for 24 h.
Lactate fluorescent substrate was added, and fluorescence was
measured, N = 4–9. *P < 0.05, ***P < 0.001 vs control (one-way
ANOVA followed by Dunnett test).
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phosphate dehydrogenase, pyruvate kinase, and lactate
dehydrogenase. The question remains which mecha-
nism is responsible for the inhibition of glycolysis by
3PO. The present study shows that the inhibitory
effect of 3PO on glycolysis relies on the ability of this
compound to cause an imbalance in pHi by accumu-
lating lactic acid inside the cell. It is known that some
glycolytic enzymes including lactate dehydrogenase
and phosphofructokinase-1 (PFK-1) are very pH sensi-
tive. A change of less than one pH unit, even a few
tenths, may reduce the activity of PFK-1 by more than
10-fold [18,19,26–28]. Moreover, PFKFB3, also known
as PFK-2, has been shown to be allosterically regu-
lated by hydrogen ion concentrations [29]. On the
other hand, lactate is an important regulator of pH
[20], and hence, the intracellular increase in this
metabolite leads to intracellular milieu acidification,
thus indirectly affecting the rate of glycolysis. Manipu-
lating intracellular acidification has been considered to
have therapeutic utility in tumors. One of the strate-
gies includes the inhibition of MCTs. Among different
acid extruders present in the cell membrane, MCTs 1
and 4 are responsible for bumping out lactate and
hydrogen ions. More specifically, a multitude of stud-
ies has documented that MCT1 or MCT4 inhibition
conferred antiangiogenic effects and block tumor
growth [30–32]. In this light, we do not rule out the
possibility that 3PO acts as an inhibitor of one or
more MCT transporters.
Altogether, our study indicates that the inhibitory
effect of 3PO on PFKFB3 enzymatic activity, glycoly-
sis, and angiogenesis is not mediated through direct
binding to the PFKFB3 protein, as already suggested
previously [6]. This is the first study to report these
findings, as no previous studies have investigated the
thermodynamic profile and biomolecular interactions
of 3PO and PFKFB3. Intracellular acidification and
lactate accumulation are followed by a chain reaction
starting with MCT1/4 inhibition, pHi decrease, influ-
ence of pH-dependent rate-limiting enzymes, and gly-
colysis suppression. This backward chain reaction
supports our hypothesis of 3PO targeting MCT 1 and
MCT 4. The identification of this target may have an
important impact on angiogenesis research and on the
development of specific antiangiogenic treatments,
which has implications for a variety of pathologies.
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